GT Biopharma announced that after the acquisition of Georgetown Translational Pharmaceuticals it has changed its stock trading symbol from OXISD to GTBP.

GT Biopharma (OTCQB:GTBP) announced that after the acquisition of Georgetown Translational Pharmaceuticals it has changed its stock trading symbol from OXISD to GTBP.
As quoted in the press release:

Earlier this month, GT Biopharma announced that it had completed the acquisition of GTP and retired more than $18 million of debt. Completion of the merger was a key step that allows GT Biopharma to consider applying for acceptance to the Nasdaq Exchange.
The Company is pursuing Food and Drug Administration approval of therapies to treat cancer and Central Nervous System disorders, including a non-opioid pain medication.

Click here to read the full press release.

Source: www.accesswire.com

acquisition biopharma cancer central nervous system central nervous system disorders food and drug administration merger pain Pharmaceutical Investing